Intra-Cellular Therapies (NASDAQ:ITCI) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI) in a research note released on Thursday. The firm issued a hold rating on the biopharmaceutical company’s stock.

ITCI has been the subject of several other reports. Piper Sandler reiterated a “neutral” rating and set a $132.00 price target (up from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Leerink Partnrs downgraded shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Mizuho downgraded shares of Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and lowered their price target for the stock from $140.00 to $132.00 in a report on Monday, February 24th. Baird R W downgraded shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Intra-Cellular Therapies in a report on Friday, February 21st. Ten investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $106.08.

Intra-Cellular Therapies Price Performance

Shares of ITCI opened at $131.65 on Thursday. Intra-Cellular Therapies has a one year low of $64.09 and a one year high of $131.67. The company has a market cap of $14.00 billion, a P/E ratio of -151.32 and a beta of 0.69. The firm has a 50 day simple moving average of $128.61 and a two-hundred day simple moving average of $97.59.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The firm had revenue of $199.22 million for the quarter, compared to analyst estimates of $205.08 million. On average, analysts expect that Intra-Cellular Therapies will post -0.64 earnings per share for the current fiscal year.

Institutional Trading of Intra-Cellular Therapies

A number of institutional investors have recently bought and sold shares of ITCI. Norges Bank bought a new stake in Intra-Cellular Therapies during the fourth quarter valued at $268,347,000. Raymond James Financial Inc. bought a new position in shares of Intra-Cellular Therapies during the 4th quarter worth about $76,451,000. Adage Capital Partners GP L.L.C. boosted its position in shares of Intra-Cellular Therapies by 266.5% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 678,000 shares of the biopharmaceutical company’s stock worth $56,627,000 after purchasing an additional 493,000 shares in the last quarter. TimesSquare Capital Management LLC boosted its position in shares of Intra-Cellular Therapies by 91.8% during the 4th quarter. TimesSquare Capital Management LLC now owns 840,269 shares of the biopharmaceutical company’s stock worth $70,179,000 after purchasing an additional 402,186 shares in the last quarter. Finally, Deep Track Capital LP boosted its position in shares of Intra-Cellular Therapies by 24.9% during the 4th quarter. Deep Track Capital LP now owns 2,000,000 shares of the biopharmaceutical company’s stock worth $167,040,000 after purchasing an additional 399,307 shares in the last quarter. Institutional investors own 92.33% of the company’s stock.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.